Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly.
Journal
Endocrinology, diabetes & metabolism case reports
ISSN: 2052-0573
Titre abrégé: Endocrinol Diabetes Metab Case Rep
Pays: England
ID NLM: 101618943
Informations de publication
Date de publication:
23 Sep 2020
23 Sep 2020
Historique:
received:
16
08
2020
accepted:
03
09
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
9
1
2021
Statut:
aheadofprint
Résumé
The coincidence of a pheochromocytoma or paraganglioma and a pituitary adenoma in the same patient is a rare condition. In the last few years SDHx and MAX mutations have been identified and discussed as a potential causal connection in cases of coincidence. We describe a case of a middle-aged female patient which presented with acromegaly, a growth hormone-secreting pituitary adenoma and a symptomatic neck paraganglioma. The patient was cured by surgery from both the pituitary tumour and the paraganglioma and is well after ten years follow-up. Due to the unusual coexistence of two neuroendocrine tumours, further molecular genetic testing was performed which revealed a variant in the TMEM127 gene (c245-10C>G). Pheochromocytoma/paraganglioma and coexisting functioning pituitary adenoma are a very rare condition. An appropriate treatment of each tumour entity with a multi-disciplinary approach and regular follow-up is needed. The possibility of a hereditary disease should be considered and genetic workup is recommended. Genetic testing should focus primarily on the genes with mutations related to pheochromocytomas and paragangliomas. Next-generation sequencing with multi-gene panel testing is the currently suggested strategy. Genes associated with paragangliomas and pituitary adenomas are SDHA, SDHB, SDHC, SDHD, SDHAF2, MAX and MEN1, while case reports with VHL, RET and NF1 may represent coincidences. Variants of uncertain significance may need ongoing vigilance, in case novel data become available of these variants.
Identifiants
pubmed: 33416299
doi: 10.1530/EDM-20-0119
pii: EDM200119
pmc: PMC7576664
doi:
pii:
Types de publication
Journal Article
Langues
eng
Références
Eur J Intern Med. 2019 Nov;69:14-19
pubmed: 31431315
Clin Biochem Rev. 2017 Apr;38(2):69-100
pubmed: 29332973
Endocrine. 2018 Jan;59(1):175-182
pubmed: 28477304
Acta Med Scand. 1952 Feb 16;142(1):1-5
pubmed: 14923268
Neoplasma. 2019 Jun 29;66(5):671-680
pubmed: 31307198
Clinics (Sao Paulo). 2012;67 Suppl 1:19-28
pubmed: 22584701
JAMA. 2010 Dec 15;304(23):2611-9
pubmed: 21156949
JAMA Oncol. 2017 Sep 1;3(9):1204-1212
pubmed: 28384794
Nat Genet. 2010 Mar;42(3):229-33
pubmed: 20154675
J Clin Endocrinol Metab. 2015 Mar;100(3):E531-41
pubmed: 25494863
Cancers (Basel). 2019 Jun 11;11(6):
pubmed: 31212687
Endocrine. 2013 Apr;43(2):293-302
pubmed: 22983831
Endocr Pathol. 2007 Spring;18(1):46-52
pubmed: 17652801
Oncotarget. 2019 Oct 15;10(57):5919-5931
pubmed: 31666924
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Cell Tissue Res. 2018 May;372(2):379-392
pubmed: 29427052
J Clin Endocrinol Metab. 2012 May;97(5):E805-9
pubmed: 22419703
Cancer Res. 2005 Nov 1;65(21):9651-8
pubmed: 16266984
Endocr Relat Cancer. 2015 Aug;22(4):T105-22
pubmed: 26113600
Hum Mol Genet. 2018 May 15;27(10):1794-1808
pubmed: 29547888
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Clin Endocrinol Metab. 2011 Aug;96(8):E1279-82
pubmed: 21613359